Expanded use trials-are there better approaches to minimize adverse consequences to the clinical trials program?
Yale Cancer Center, New Haven, CT.
Mario
M
Sznol
D005260:Female; D006801:Humans; D007211:Indoles / Q000627:therapeutic use*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000188:drug therapy*; D013449:Sulfonamides / Q000627:therapeutic use*; D000077484:Vemurafenib
D007211:Indoles; D013449:Sulfonamides; D000077484:Vemurafenib